Sound Pharmaceuticals, Incorporated

This study tested an experimental drug called SPI-1005 (ebselen) in 254 adults with Meniere's disease, a condition causing hearing loss, ringing in the ears, and dizziness. Participants received either the drug or a placebo for a set period, followed by an open-label phase where …

This study tests whether SPI-1005, a drug containing ebselen, can prevent hearing loss in people with cystic fibrosis who are receiving IV tobramycin for a lung infection. About 40 participants will receive either a placebo or one of three doses of SPI-1005 for 21 days. Researche…

This study tests an experimental drug called SPI-1005 (ebselen) in adults hospitalized with severe COVID-19. Participants receive either the drug or a placebo to see if the drug is safe and helps improve recovery. The trial is randomized and double-blind, meaning neither patients…

This study tested whether an oral drug called SPI-1005 could prevent temporary hearing changes caused by listening to loud music through headphones. 83 healthy adults took either the drug or a placebo for 4 days. The drug works by helping the body get rid of harmful chemicals pro…

This study tests an experimental drug called SPI-1005 (ebselen) in adults with Meniere's disease, a condition that causes vertigo, tinnitus, and hearing loss. The trial compares three doses of SPI-1005 against a placebo to see if it safely reduces these symptoms. Researchers will…